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GENERAL INTRODUCTION 
 
 
 Analytical Chemistry deals with methods for determining the chemical composition 
of samples of matter. A quantitative method yield information about the identity of atomic or 
molecular species or the functional groups in the sample, a quantitative method, in contrast, 
provides numerical information as to the relative amount of one or more of these 
components.  
 In Analytical Chemistry  it is to prime importance to gain information about the 
qualitative and quantitative composition of substance and chemical species, that is to find out 
what a substance is composed and exactly how much. The goal of chemical analysis is to 
provide information about the composition of a sample of matter. In instrumental analysis, a 
physical property of a substance is measured to determined its chemical composition.1 
  
1.1. CLASSIFICATION OF ANALYTICAL METHODS 
Analytical methods are often classified as being either classical or instrumental. This 
classification is largely historical with classical methods, sometimes called wet chemical 
methods preceding instrumental methods by a century or more.  
 
Classical Method 
 In the early years of chemistry, most analysis were carried out by separating the 
components of interest (the analytes) in a sample by precipitation, extraction, or distillation. 
For qualitative analysis, the separated components were then treated with reagents that 
yielded products that could be recognized by their colours, their boiling or melting points, 
their solubilities in a series of solvents, or their refractive indexes. For quantitative analysis, 
the amount of analyte was determined by gravimetric or by titrimetric measurements. In  
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gravimetric measurements, the mass of the analyte or some compound produced form the 
analyte was determined. In titrimetric procedure, the volume or mass of a standard reagent 
required to react completely with the analyte was measured.  
 
Instrumental Method 
 Early in the twentieth century, chemists began to exploit phenomena other than those 
used for classical methods for solving analytical problems. Thus physical properties of 
analytes such as conductivity, electrode potential, light absorption or emission, mass-to 
charge ratio, and fluorescence began to be used for quantitative analysis of a variety of 
inorganic, organic and bio-chemical analytes. Furthermore, highly efficient chromatographic 
and electrophotometric techniques began to replace distillation, extraction, and precipitation 
for the separation of components of complex mixtures prior to their qualitative or quantitative 
determination. These newer methods for separating and determining chemical species are 
known collectively as instrumental method of analysis.2 
  
The instrumental technique can be categorized into following types :- 
A. Spectrophotometric technique : 
1. Colorimetry 
2. UV – Visible Spectrophotometry  
3. Fluorescence and Phosphorescence spectrometry. 
4. Atomic spectrometry 
5. Infrared spectrometry  
6. X-ray diffraction Method 
7. Nuclear magnetic resonance spectrometry.  
8.  Electron spin resonance spectrometry. 
9. Turbidimetry 
10. Nephlomery etc. 
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B.Electrochemical Technique : 
1. Conductometry 
2. Potentiometry 
3. Coulometry 
4. Voltametry 
5. Electro gravimetry 
 
C. Chromatographic techniques : 
1. Thin layer chromatography. 
2. Gas chromatography 
3. Super critical fluid chromatography 
4. High performance liquid chromatography  
 
D. Miscellaneous techniques : 
1. Thermal analysis 
2. Mass spectrometry 
3. Kinetic technique  
 
E. Hyphenated techniques : 
1. LC – MS 
2. LC – NMR 
3. GC – MS 
 
Table – 1 
Classification of Analytical Methods  
Characteristic Properties  Instrumental Methods  
Emission of radiation Emission spectroscopy (X-ray, UV, visible electron fluorescence, phosphorescence, and luminescence.  
Absorption of radiation 
Spectrophotometric and photometry (X-ray, UV, visible, 
IR), nuclear magnetic resonance and electron spin 
resonance spectroscopy.  
Scattering of radiation Turbidimetry; nephelometry, Raman spectroscopy  
Refraction of radiation  Refractrometry; interferometry 
Diffraction of radiation X-ray and electron diffraction methods   
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Rotation of radiation Polarimetry, optical dispersion; circular dichrosim 
Electrical potential Potentiometry; chronopotentiometry 
Electrical charge Coulometry 
Electrical current  Amperometry; polarography 
Electrical resistance  Conductometry 
Mass Gravimetry 
Mass-to-charge ratio Mass spectrometry 
Thermal characteristics  
Thermal gravimetry and titrimetry, differential scanning 
colorimetry; differential thermal analysies; thermal 
conductometric methods. 
Radioactivity  Activation and isotope dilution methods  
 
2.SPECTROSCOPY 
 Spectroscopy is a general term for the science that deals with the interaction of 
various types of radiation with matter. Spectroscopy and spectroscopic methods refer to the 
measurement of the intensity of radiation with  a photometric transducer or other type of 
electronic device.  
 Analytical application of the absorption of radiation by matter can be either 
qualitative or quantitative. The qualitative and quantitative application of absorption 
spectrometry depend on the fact – 
¾ A given molecular species absorbs radiation only in specific regions of the spectrum 
where the radiation has the energy required to raise the molecules to some excited 
state.  
 A display of absorption versus wavelength (or frequency) is called an absorption  
spectrum of that molecular species and services as a fingerprint for identification.3 
 
 
 
 
5 
 
Chapter I                                                                                                                              Introduction 
 
 
 
2.1. UV SPECTROPHOTOMETRY 
 The technique of UV spectrophotometry is one of the most frequently employed in 
pharmaceutical analysis. It involves the measurement of the amount of UV (190-380nm) or 
visible (380-800nm) radiations absorbed by a substance in solution. 
 Molecular absorption in the ultraviolet (UV) and visible region of the spectrum is 
dependent on the electronic structure of the molecule. Absorption of energy is quantized, 
resulting in the elevation of electrons from orbitals in the ground state to higher energy 
orbital spin an excited state. For many electronic structures, the absorption does not occur in 
the readily accessible portion of the UV region. In practice, UV spectrometry is normally 
limited to conjugated systems [4] 
 Molecular absorption spectroscopy is based on the measurement of the transmittance 
(T) or the absorbance (A) of solutions contained in transparent cells having a path length of 
(b) cm. ordinarily, the concentration (c) of a absorbing analyte is linearly related to 
absorbance as represented by the equation.  
 A =  - log T   = log Po/p   = ∈bc    
This equation is a mathematical representation of Beer’s law. [2] 
 Instruments which measure the ratio, or a function of the ratio,  of the intensity of two 
beams of light in the UV region are called UV spectrophotometers. Absorption of light in 
both the UV and visible region of the electromagnetic spectrum occurs when the energy of 
light matches that required to induce in the molecule an electronic transition and its 
associated vibrational and rotational transitions.  
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3. CHROMATOGRAPHY 
 Chromatography encompasses a diverse and important group of methods that permit 
the scientist to separate closely related components of complex mixtures, many of these 
separations are impossible by other means. In all chromatographic separations the sample is 
transported in a mobile phase, which may be a gas, a liquid, or a supercritical fluid. This 
mobile phase is then forced through an immiscible stationary phase, which is fixed in place in 
a column or on a solid surface. The two phases are chosen so that the components of the 
sample distribute themselves between the mobile and stationary phase to varying degrees. 
Those components that are strongly retained by the stationary phase move only slowly with 
the flow of mobile phase. In contrast, components that are weakly held by the stationary 
phase travel rapidly. As a consequence of these differences in mobility, sample components 
separate into discrete hands, or zones, that can be analyzed qualitatively and / or 
quantitatively. 
 Chromatography can be defined as chemical separation technique based on the 
differential distribution of the constituents of a mixture between two phases, one of which 
moves relative to the other. 
 A fundamental classification of chromatographic methods is based upon the types of 
mobile and stationary phases and the  kinds of equilibria involved in the transfer of solutes 
between phases. There are three general categories of chromatography, liquid 
chromatography, gas chromatography and supercritical chromatography. As the names imply, 
the mobile phases in the three techniques are liquids, gases and supercritical fluids 
respectively. 2 
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Table 2 
Classification of Chromatography 
General 
Classification Specific Method Stationary Phase Type of Equilibrium  
Liquid 
Chromatography 
(LC) (mobile 
phase liquid) 
Liquid – liquid, or 
partition  
Liquid absorbed on 
solid  
Partition between 
immiscible liquids  
Liquid- bonded phase Organic species bonded to a solid surface 
Partition between 
liquid and bonded 
surface  
Liquid – solid-
adsorption Solid  Adsorption  
Ion-exchange resin Ion-exchange resin Ion exchange  
Size exchange Liquid in interstices of a polymetric solid Partition/sieving  
Gas 
Chromatography 
(GC) (mobile 
phase gas) 
Gas- liquid  Liquid adsorbed on a solid 
Partition between gas 
and liquid 
Gas – bonded phase Organic species boned to a solid surface 
Partition between 
liquid and bonded 
surface 
Gas – solid  Solid  Adsorption 
 Organic species bonded to a solid surface  
Partition between 
supercritical fluid and 
bonded surface  
 
 
3.1 LIQUID CHROMATOGRAPHY  : 
 Liquid chromatography is a method of chromatographic separation based on the 
difference in the distribution of species between two non-miscible phases, in which the 
mobile phase is a liquid which percolates through a stationary phase contained in a column. 
 Liquid chromatography is mainly based on mechanisms of adsorption, mass 
distribution, ion exchange, size exclusion or stereo chemical interaction. 5 
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3.2 HIGH – PERFORMANCE LIQUID CHROMATOGRAPHY 
 High performance liquid chromatography (HPLC) is the fastest growing analytical 
technique for the analysis of drugs. Its simplicity, high specificity, and wide range of 
sensitivity make it ideal for the analysis of many drugs in both dosage forms and biological 
fluids. The  rapid growth of the HPLC has been facilitated by the development of reliable, 
moderate priced instrumentation and efficient  columns. Separation efficiencies achievable 
today are five to ten times greater than those available in the early.  
 
Depending upon the mobile phase HPLC method can be classified into following types  
1. Liquid – liquid chromatography (LLC) 
2. Liquid – solid chromatography (LSC) 
3. Ion – exchange chromatography 
4. Size – exclusion chromatography  
 Liquid – solid chromatography often called the adsorption chromatography and 
liquid- liquid chromatography is  termed partition chromatography, LLC can be divided into 
normal or reversed phase chromatography.  
 Liquid – solid chromatography or adsorption chromatography implies high surface 
area particles that adsorb the solute molecules. Usually a polar solid such  as silica gel, 
alumina (Al2O3) or porous glass beads and non-polar mobile phase such as heptanes, octane, 
or chloroform are used in adsorption chromatography, the differences in affinity of the 
solutes for the surface of the stationary phase account for the separations achieved. The 
compound has little affinity for the stationary phase and hence elutes quickly. The compound 
has a much higher affinity and is retained longer in the system. Generally, in adsorption 
HPLC, compounds elute in the reverse order of their polarities. 
 In liquid-liquid or partition chromatography, the solid support is coated with a liquid 
stationary phase. The relative distribution of solutes between the two liquid phases  
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determines the separation. The stationary phase can be either polar or non-polar. If the 
stationary phase is polar and the mobile phase is non-polar, it is called normal –phase 
partition chromatography. If the opposite case holds, it is called reversed phase partition 
chromatography. In the normal phase mode, the polar molecules partition preferentially into 
the stationary phase and are retained longer than non-polar compounds. In reversed phase 
partition chromatography, the opposite behavior is observed.  
 Ion-exchange chromatography uses stationary phases that can exchange cationic or 
anionic species with the mobile phase. In this mode, a reversible exchange of ions takes place 
between the stationary ion-exchange phase and the liquid mobile phase. Separations are 
achieved due to the differences in strength of electrostatic interactions of the solutes with the 
stationary phase.  
 Gel-permeation or size-exclusion chromatography are methods based on separation 
according to the size of the molecules. In this type of chromatography, the materials used for 
the stationary phases contain pores of certain sizes. Molecules that are too large are excluded 
from the pores while smaller molecules enter into the pores. The larger molecules remain in 
the following mobile phase and are eluted first. The smaller molecules, while in the pores, do 
not travel as fast and are eluted last. 6 
 
3.3 REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
 Reverse phase chromatography refers to the use of a polar eluent with a non polar 
stationary phase in contrast to normal phase chromatography, where a polar stationary phase 
is employed with anon – polar mobile phase.  
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Reverse phase chromatography is widely used due to the following advantages 
¾ Many compounds such as biologically active substances have limited solubility in non 
polar solvents that are employed in normal phase chromatography. 
¾ Ionic or highly polar compounds have high heats of adsorption on straight silica or 
alumina columns and therefore can elute as a tailing peaks.  
¾ Column deactivation from polar modifiers is a problem in liquid solid  
chromatography which frequently leads to irreducibility in chromatography systems.  
¾ Ionic compounds can be chromatographed via ion exchange chromatography. This 
mode of chromatography is tedious because precise control of variables such as pH 
and ionic strength is required for reproducible chromatography. 
 
Reverse phase mobile phases   
 The mobile phase in RPHPLC, however, has a great influence on the retention of the 
solutes and the separation of component mixtures. 
 The primary constituent of reverse phase-mobile phase is water. Water miscible 
solvents such as methanol, ethanol, acetonitrile, dioxin, tetrahydrofuran are added to adjust 
the polarity of the mobile phase. The water should be high quality, either distilled or 
demineralised. The most widely used organic modifiers are methanol, acetonitrile and 
tetrahydrofuran. Methanol and acetonitrile have comparable polarities but the latter is an 
aportic solvent. This factor may be important if hydrogen bonding plays a significant role in 
the separation. When organic salts and ionic surfactants are used, the mobile phase should be 
filtered before use since these additives frequently contain a significant amount of water 
insoluble contaminants that may damage the column. Reverse phase mobile are  
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generally noninflammable due to high water content. Degassing is quite important 
with reverse phase mobile phases. 
 
Selection of Mobile Phase  
Flowing points are considered for the selection of a mobile phase.  
1. Viscosity. 
2. Compressibility 
3. Refractive index 
4. UV cutoff 
5. Polarity  
6. Vapour pressure 
7. Flash point.  
 
 
Reverse Phase HPLC Detectors  
 Detectors for HPLC fall into general categories. Differential detectors or bulk 
property detectors provide a differential measurement of a bulk property that is possessed by 
both the solute and the mobile phase. These detectors are generally nonspecific and respond 
to a wide range of compounds. eg. Refractive index detectors. The solute property or 
selective detectors measures a property of the sample which is not possessed by the mobile 
phase, eg. Ultraviolet and fluorescence detectors.  
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4. VALIDATION 
 Validation is defined by different agencies.  
USFDA : According to this “Validation is the process of establishing documented evidence 
which provides a high degree of assurance that a specific process will consistently produce a 
product meeting its predetermined specifications and quality attributes.  
WHO : Defines Validation as an action of providing any procedure, process, 
equipment, material, activity or system actually leads to the expected results.  
EUROPEAN COMMITTEE: Defines Validation as an action of providing in accordance 
with the principles of GMP that any procedure, process, material, activity or system actually 
lead to expected results.  
 This process consists of establishment of the performance characteristics and the 
limitations of the method.  
Objective  
 The objective of validation of an analytical procedure is to demonstrate that it is 
suitable for its intended purpose & it gives the assurance that the drug product have the 
identify strength, quality and purity.  
a) Quality, safety and efficacy must be designed and built into the product. 
b) Each step of the manufacturing process must be controlled to maximize the 
probability that the finished product meets all quality and design specification.  
 
When validation is needed 
• For the introducing a new method in routine use. 
• Whenever  change in the synthesis of drug substance 
• Whenever change in the composition of the finished product. 7 
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Requirement for validation 
• Calibration report of instruments 
• A targeted goal to be achieved 
• Protocols 
• A procedure of validation that is validated 
• All the documents of prevalidated documentation procedure. 
• Reviewing of all the predetermined intervals or events. 
• Authentication of all the above by individuals who are considered to be fir for 
authentication. 
Whatever is not validated is considered to be invalid or unfit for use 8 
 
Types of analytical procedures to be validated 
Four most common types of analytical procedures to be validated 
• Identification test 
• Quantitative test for impurities content 
• Limit tests for the control of impurities 
• Quantitative tests of the active moiety in samples of drug substance or drug 
product or other selected component(s) in the drug product. 9 
 
Purpose for validation 
• Enable scientists to communicate scientifically and effectively on technical 
matters. 
• Setting standards of evaluation procedures for checking compliance and taking 
remedial measures. 
14 
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• Reduction in cost associated with process sampling and testing. The 
consistency and reliability of validated analytical procedure is to produce a 
quality product with all the quality attributes thus providing indirect cost 
saving from reduced testing or re-testing and elimination of product rejection. 
• As quality of the product cannot always be assured by routine quality control 
because of testing of statistically insignificant number of samples, the 
validation thus shall provide adequacy and reliability of a system or a 
procedure to meet the pre-determined criteria attributes providing high degree 
of confidence that the same level of quality is consistently built into each unit 
of finished product from batch to batch. 
• Retrospective validation is useful for trend comparison of results compliance 
to cGMP/cGLP. 
• Closer interaction with pharmacopoeial forum to address analytical problems. 
• International pharmacopoeial harmonization particularly in respect of 
impurities determination and their limits. 
• For taking appropriate action in case of non-compliance. 
 
Selection of analytical method 
 First stage in the selection or development of method is to establish what is to be 
measured and how accurately it should be measured. Unless one has series of method at hand 
to assess quality of the product, validation, programme may have limited validity. The 
selected method must have the following parameters. 
1. As simple as possible 
2. Most specific 
3. Most productive, economical and convenient 
15 
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4. As accurate and precise as  required. 
5. Multiple source of key components (reagents, columns, TLC plates) should be 
avoided. 
6. To be fully optimized before transfer for validation of its characteristics such 
as accuracy precision, sensitivity, ruggedness etc. 10 
4.1 ANALYTICAL METHOD VALIDATION 
 Method validation is a process of establishing performance characteristics and 
limitations of a method and identification of the influences which may change the 
characteristics and to what extent. It is also used for solving a particular analytical problem. 
 Validated analytical test methods are required by good manufacturing practice (GMP) 
regulations for products that have been authorized for sale and almost certainly for late-stage 
trial clinical material. Also, some methods used during the pre-clinical phase of drug 
development under good laboratory practice (GLP) regulations may also require validation. 
 “Validation of an analytical method is the process by which it is established, by 
laboratory studies, that the performance characteristics of the method meet the requirements 
for the intended analytical applications”. 
 Analytical validation is the core stone of process validation without a proven 
measurement system it is impossible to confirm whether the manufacturing process has done 
what it purports to do. 
 It is the process of  proving that an analytical method is acceptable for its intended 
purpose. For pharmaceutical methods, guidelines from the united states Pharamacopoeia 
(USP), international conference on Harmonization (ICH) and the food and drug 
administration (FDA) provide a framework for performing such validations. 
16 
 
 The purpose of method validation is to demonstrate that the established method 
is “fit for the purpose”. This means that the method, as used by the laboratory 
generating the data, will provide data that meets the criteria set in the planning phase. 
There is not a single accepted procedure for conducting a method validation. Much of 
the method validation and development are performed in an interative manner, with 
adjustments or imporovements to the method made as dictated by the data. The analyst’s 
primary objective is to select an approach that will demonstrate a true validation while 
working in a situation with defined limitations, such as cost and time. All new methods 
developed are validated. 
 
Assay Category I 
 Analytical method for quantitation of major components of bulk drug substances or 
active ingredients (including preservatives) in finished pharmaceutical products. 
 
Assay Category II 
 Analytical method for determination of impurities in bulk drug substances or 
degradation compounds in finished pharmaceutical products. These methods include 
quantitative assays and limit tests. 
 
Assay Category III 
 Analytical method for determination of performance characteristics. (E.g. dissolution, 
drug release profile). 
 
 
 
 
17 
 
Chapter I                                                                                                                              Introduction 
 
 
 
Assay Category IV 
 Identification tests 
 For each assay category, different analytical information is needed. Data elements that 
is normally required for each of the categories of assays given in the following table. 
Table 3 
Data elements required for assay validation as per USP 
 
Parameters 
Assay 
Category 
I 
Assay Category II Assay 
Category III 
Assay 
Category IV Quantitative Limit Tests 
Specificity or 
selectivity Yes Yes * * No 
Accuracy Yes Yes No Yes No 
Precision Yes Yes Yes * Yes 
Detection Limit No No Yes * No 
Quantitation 
Limit No Yes No * No 
Linearity Yes Yes No * No 
Range Yes Yes * * No 
 
Analytical method validation parameters 
¾ Accuracy 
¾ Precision 
¾ Specificity 
¾ Limit of Detection 
¾ Limit of Quantitation 
¾ Linearity and Range 
18 
 
¾ Ruggedness 
¾ Robustness 
¾ System suitability 
 Method validation is completed to ensure that an analytical methodology is accurate, 
specific, reproducible and rugged over the specified range that an analyte will be analyzed. 
Method validation provides an assurance of reliability during normal use, and is 
sometime referred to as “the process of providing documented evidence that the method does 
what it is intended to do.” Regulated laboratories must perform method validation in order to 
be in compliance with FDA regulation. 
 
Accuracy 
 Accuracy is the measure of exactness of an analytical method, or the closeness of 
agreement between the value which is accepted either as a conventional, true value or an 
accepted reference value and the value found. It is measure as the percent of analyte 
recovered by assay. 
 
Precision 
 Precision is the measure of the degree of repeatability of an analytical method under 
normal operation and is normally expressed as the percent relative standard deviation for a 
statistically significant number of samples. According to the ICH, precision should be 
performed at three different levels: repeatability, intermediated precision, and reproducibility. 
1. Repeatability is the results of the method operating over a short time interval 
under the same conditions (inter-assay precision). It should be determined from a 
minimum of nine determinations covering the specified range of the procedure 
(for example, three levels, three repetitions each) or from a minimum of six 
determinations at 100% of the test or target concentration. 
19 
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2. Intermediate precision is the results from within lab variations due to random 
events such as different days, analysts, equipment, etc. in determining 
intermediate precision, experimental design should be employed so that the 
effects (if any) of the individual variables can be monitored. 
3. Reproducibility refers to the results of collaborative studies between laboratories. 
Documentation in support of precision studies should include the standard 
deviation, relative standard deviation, coefficient of variation, and the confidence 
interval. 
 
Specificity 
 Specificity is the ability to measure accurately and specifically and analyte of interest 
in the presence of other components that may be expected to be present in the sample matrix. 
It is a measure of the degree of interference from such things as other active ingredients, 
excipients, impurities, and  degradation products, ensuring that a peak response is due to 
single component only. 
Limit of Detection 
 The limit of detection (LOD) is defined as the lowest concentration of an anlayte in a 
sample that can be detected, not quantitated. It is a limit test that specifies whether or not an 
analyte is above or below a certain value. It is expressed as a concentration at a specified 
signal-to-noise ratio, usually two-or three-to-one. 
 LOD’s may also be calculated based on the standard deviation of the response (σ) and 
the slope of the calibration curve (S) at levels approximating the LOD according to the 
formula: 
LOD = 3.3(σ/S) 
20 
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Limit of Quantitation 
 The Limit of Quantitation (LOQ) is defined as the lowest concentration of an analyte 
in a sample that can be determined with acceptable precision and accuracy under the stated 
operational conditions of the method. Like LOD, LOQ is expressed as a concentration, with 
the precision and accuracy of the measurement also reported. Sometimes a signal-to-noise 
ratio of ten-to-one is used to determine LOQ. This signal-to-noise ratio is a good rule of 
thumb, but it should be remembered that the determination of LOQ is a compromise between 
the concentration and the required precision and accuracy. That is, as the LOQ concentration 
level decreases, the precision increases. If better precision is required, a higher concentration 
must be reported for LOQ. 
 The calculation method is again based on the standard deviation of the response (σ) 
and the slope of the calibration curve (S) according to the formula: 
LOQ = 10(σ/S) 
Linearity and Range 
 Linearity is the ability of the method to elicit test results that are directly proportional 
to analyte concentration within a given range. Linearity is generally reported as the variance 
of the slope of the regression line. Range is the interval between the upper and lower levels of 
analyte (inclusive) that have been demonstrated to be determined with precision, accuracy 
and linearity using the method as written. The range is normally expressed in the same units 
as the test results obtained by the method. 
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Ruggedness 
 Ruggedness, according to the USP, is the degree of reproducibility of the results 
obtained under a variety of conditions, expressed as %RSD. These conditions include 
different laboratories, analysts, instruments, reagents, days, etc. 
 
Robustness 
 Robustness is the capacity of a method to remain unaffected by small deliberate 
variations in method parameters. The robustness of a method is evaluated by varying method 
parameters such as percent organic, pH, ionic strength, temperature, etc., and determining the 
effect (if any) on the results of the method. 
 
System Suitability 
 According to the USP, system suitability tests are an integral part of chromatographic 
methods. These tests are used to verify that the resolution and reproducibility of the system 
are adequate for the analysis to be performed. System suitability tests are based on the 
concept that the equipment , electronics, analytical operations, and samples constitute an 
integral system that can be evaluated as a whole. 
 System suitability is the checking of a system to ensure system performance before or 
during the analysis of unknowns. Parameters such as plate count, tailing factors, resolution 
and reproducibility are determined and compared against the specifications set for the 
method. These parameters are measured during the analysis of a system suitability “sample” 
that is a mixture of main components and expected by-products. 9, 11, 12 
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4.2. MERITS AND DEMERITS OF ANALYTICAL METHOD VALIDATION 
Merits 
• Reliability of analytical results and assurance of quality product. 
• Performance capability of the method can be confirmed by analysts using the 
method. 
• Awareness about importance of protocols for validation work. 
• Motivation for improvement in quality of work. 
• Provides opportunity for training to QC staff. 
• Helps in scientific communication on technical matters. 
 
Demerits 
• Increasing cost. 
•  Need for experienced personnel. 13 
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DRUG PROFILE 14, 15, 16 
MONTELUKAST SODIUM 
Molecular structure: 
                  
              
NCl S
OH
OH
O
 
 
Chemical Name            :  [R-(E)]-1-(((1-(3-(2-(7-chloro-2-quinolinyl) ethenyl)   
                                         Phenyl)-3-(2-(1-hydroxy-1-methyl ethyl)phenyl)   
                                         Propyl) thio)methyl) cyclopropane acetic acid. 
 
Molecular Formula      :  C35H36ClNO3S 
 
Molecular Weight        :   586.18 
 
Appearance                   :  White or almost white powder 
 
Solubility                       : Soluble in methanol, Insoluble in 0.1 N HCl, Partially  
                                         soluble in distilled water.      
 
Action and use              :  Anti-ashmatic drug. 
24 
 
Chapter II                                                                                                                              Drug Profile 
 
BAMBUTEROL HYDROCHLORIDE 14, 15, 16, 17                  
Molecular structure:                                  
 
                                    
OO
O N
CH3
CH3
ON
CH3
CH3
OH NH
CH3CH3
CH3
 
 
 
Chemical Name            :  [3[2(tert-butyl amino)-1-hydroxy ethyl]-5-(dimethyl  
                                           carbamoyl oxy)-phenyl] N,N dimethyl carbamate.  
 
 
Molecular Formula      :  C18H29N3O5 
 
Molecular weight          :      367.440 
 
Appearance                   :   White or almost white powder 
 
Solubility                       :    soluble in methanol       
 
Action and use              :   Antiashmatic drug. 
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REVIEW OF LITERATURE 
 
 Alsarra et al., developed a stability-indicating HPLC method for the determination 
of Montelukast in tablets and human plasma and its application to pharmacokinetic and 
stability studies. The intra day and interday precisions showed coefficients of variations 
ranged from 5.87% to 9.60% and from 2.13% to 6.18% at three different levels of 
concentrations.18 
          Radhakrishna et al., compared HPLC and derivative spectrophotometric methods 
for the simultaneous determination of Montelucast and Loratidine. HPLC separation was 
achieved with a symmetry C18 column and sodium phosphate buffer (pH 3.7): 
acetonitrile(20:80v/v) as eluent at a flow rate of 1.0 ml/min . UV detection was performed at 
225 nm. In the UV second- order derivative spectrophotometry for the determination of 
Loratidine the zero-crossing technique was applied at 276.1 nm but for Montelucast peak 
amplitude at 359.7 nm (Tangent method) was used.19 
   Liu-L et al., developed a stereo selective HPLC with column switching for the 
determination of Montelucast and its enantiomer in human plasma.20 
               Alsarra et al., Developed a spectrofluorimetric determination of Montelukast in 
dosage forms and spiked human plasma. The highest fluorescence intensity was obtained in 
methanol at 390 nm using 340 nm for excitation.21 
               Amin RD et al., carried the determination of Montelukast-0476 in human plasma 
by HPLC. The method involves precipitation of protein and reversed-phase HPLC with 
fluorescence detection. The assay is linear in the range of 30-3000 ng/ml-1 of MK-0476 and 
the limit of detection is 5 ng/ml-1. The interday accuracy values at these concentrations are 
94 and 104% respectively. The absolute recovery of MK-0476 is 99%.22 
            Alsarra et al., developed a voltammetric determination of Montelukast sodium in 
dosage forms and human plasma. It was studied using cyclic voltammetry, direct current 
(DCT) differential pulse polarography (DPP) and alternating current (ACT) Polarography. 
The mean percentage recovery (n=5) was 101.38+/- 3.85. The number of electrons  
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transferred in the reduction process could be accomplished and a proposal of the electrode 
reaction was proposed.23 
               Ibrahim A. Alsarra developed a  stability-indicating high performance liquid 
chromatographic (HPLC) method has been developed and validated for the determination of 
montelukast in human plasma and in its pharmaceutical dosage from. The proposed method 
has been also applied for the determination of montelukast in the presence of its degradation 
product. Acetonitrile: potassium dihydrogen phosphate (0.05 M) adjusted to pH 3.5 ± 0.1 
with phosphoric acid (70:30, % v/v) was used as the mobile phase at a flow rate of 2.0 
ml/min using a Symmetry C18 column. The effluent was spectrophotometrically monitored at 
345 nm. Peak area ratio of the drug to the internal standard (flufenamic acid) was used for the 
quantification of montelukast in plasma samples and the limit of quantification was 10 ng/ml 
and the limit of detection was 1.0 ng/ml. The intraday and interday precisions showed 
coefficients of variation ranged from 5.87% to 9.60% and from 2.13% to 6.18% at three 
different levels of concentrations. 24 
            Shamkant S. Patil, Shinde Atul et al., determination of Three simple, precise and 
economical UV methods have been developed for the estimation of Montelukast in bulk and 
pharmaceutical formulations. Montelukast has the absorbance maxima at 359nm (Method A), 
and in the first order derivative spectra, showed zero crossing at 359nm, with a sharp peak at 
340.5nm when n=1 (Method B), Method C applied was Area Under Curve (AUC). For 
analysis of Montelukast the wavelength range selected was 350-370 nm. Drug followed the 
Beer’s Lamberts range of 5-40 μg/ml for the Method A, B C. Results of analysis were 
validated statistically and by recovery studies and were found to be satisfactory.25 
                      Lin Zhu, Likun Chen, BinGuo et al., A chiral chromatography/tandem mass 
spectrometry bioanalytical method for the determination of bambuterol and terbutaline and 
their enantiomers in rat plasma was developed. The method employed protein precipitation 
method for sample extraction. A Chirobiotic T Spherical column was used for chiral 
separation using a polar organic mobile phase consisting of methanol and 0.2mmol/L 
ammonium formate. The analytes were detected by a tandem mass spectrometer operated in 
positive ion mode. The (S)- and (R)-isomers of bambuterol were resolved 
chromatographically with retention times of 23.42 and 20.89 min, respectively. The (S)- and 
(R)-isomers of terbutaline was 18.25min and 16.08min, respectively. The analytical run time  
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was 30 min. The lower limit of quantitation (LLOQ) was 5ng/mL for both enantiomers. The 
polar organic mode chiral chromatography provided a specific, rugged method for the chiral 
analysis of bambuterol in biological fluids.26 
C. Bosch Ojeda, F. Sanchez Rojas et al., Derivative spectrophotometry is an 
analytical technique of great utility for extracting both qualitative and quantitative 
information from spectra composed of unresolved bands, and for eliminating the effect of 
baseline shifts and baseline tilts. It consists of calculating and plotting one of the 
mathematical derivatives of a spectral curve. Thus, the information content of a spectrum is 
presented in a potentially more useful form, offering a convenient solution to a number of 
analytical problems, such as resolution of multi-component systems, removal of sample 
turbidity, matrix background and enhancement of spectral details. Derivative 
spectrophotometry is now a reasonably priced standard feature of modern micro-
computerized UV/Vis spectrophotometry.27 
Rosa Ventura, Lúcia Damasceno et al, Acomprehensive gas chromatographic–mass 
spectrometric (GC–MS) procedure for detection in urine ofb2-agonists having different alkyl 
or phenylalkyl chains at the nitrogen atom is described. The method is based on an enzymatic 
hydrolysis with b-glucuronidase from Helix pomatia, followed by a solid-phase extraction 
procedure using Bond Elut Certify columns. The influence of urinepHin the extraction 
recovery has been studied andpH9.5was found to give best recovery and cleaner extracts. 
After pH adjustment, the sample was applied to the pre-conditioned cartridges and after a 
washing step, the b2-agonists were eluted with a mixture of chloroform and isopropanol 
(80:20, v/v) containing 2% ammonia. The residues were derivatised with N-methyl-N-
trimethylsilyl-trifluoroacetamide (MSTFA), and analysed by GC–MS.Avalidation procedure 
for qualitative analysis of b2-agonists in urine was performed.28 
 Nitesh K. Patel, Gunta Subbaiah et al., A rapid liquid chromatography–electrospray 
ionization–tandem mass spectrometry (LC-ESI-MS=MS) method was developed for the 
determination of montelukast in human plasma. The extraction of montelukast from 
plasma(300 mL) involved protein precipitation. Quantitation was performed using LC-ESI-
MS=MS, operating in the positive ion and selective reaction monitoring (SRM) mode. The 
total chromatographic run time for the analysis was 1.5 min. A linear dynamic range was  
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established from 5 to 800 ng mL_1 for montelukast. The method was fully validated 
especially with regard to real subject sample analysis.29 
 D. Vijaya Bharathi, Kishore Kumar et al.,  A highly sensitive, rapid assay method 
has been developed and validated for the estimation of montelukast (MTK) in human plasma 
with liquid chromatography coupled to tandem mass spectrometry with electro spray 
ionization in the positive-ion mode. Liquid–liquid extraction was used to extract MTK and 
amlodipine (internal standard, IS) from human plasma.Chromatographic separation was 
achieved with 10mM ammonium acetate (pH 6.4): acetonitrile (15:85, v/v) at a flow rate 
of0.50 mL/min on a Discovery HS C18 column with a total run time of 3.5min. The MS/MS 
ion transitions monitored were 586.10 → 422.10 for MTK and 409.20 → 238.30 for IS. 
Method validation and clinical sample analysis were performed as per FDA guidelines and 
the results met the acceptance criteria. The lower limit of quantitation achieved was 0.25 
ng/mL and linearity was observed from 0.25 to 800 ng/mL. The intra-day and inter-day 
precisions were 5.97–8.33 and 7.09–10.13%, respectively. 30 
 M. Saeed Arayne, Najma Sultana et al., A simple ultraviolet spectrophotometric 
method for the estimation of montelukast in methanol has been devised and been compared 
with the existing pharmacopoeial RP-HPLC method for estimation of the drug. The limit of 
detection of montelukast at 283 nm was 75.2 ng/mL. The calibration was linear in the range 
of 3–45 μg/mL. Analytical parameters such as stability, selectivity, accuracy and precision 
have been establishedfor the method in MONAKA® tablets and in human serum and 
evaluated statistically to assess the application of the method. The method was validated 
under the ICH and USP guidelines and found to comprise the advantages for simplicity, 
stability, sensitivity, reproducibility and accuracy for using as an alternate to the existingnon-
spectrophotometric methods for the routine analysis of the drug in pharmaceutical 
formulations and in pharmaceutical investigations involving montelukast.31 
Hisao Ochiai, Naotaka Uchiyama et al., MK-0476 (montelukast sodium) is a potent 
and selective cysteinyl leukotriene receptor antagonist that is being investigated in the 
treatment of asthma. A simple and sensitive method for the determination of MK-0476 in 
human plasma was developed using column-switching high-performance liquid 
chromatography (HPLC) with fluorescence detection. A plasma sample was injected directly  
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onto the HPLC system consisting of a pre-column (Capcell pak MF) and an analytical 
column (Capcell pak C18) which were connected with a six-port switching valve. The 
column eluate was monitored with a fluorescence detector (excitation at 350 nm; emission at 
400 nm). The calibration curve was linear in a concentration range 21 of 1–500 ng ml for 
MK-0476 in human plasma. The intra-day coefficients of variation of all concentrations 
within the range was less than 9.2%, and the intra-day accuracy values were between 97.2 
and 114.6%. This method was used to measure the plasma concentration of MK-0476 
following oral administration of the drug in humans.32 
 Martin Josefsson, Alma Sabanovic et al, Alternative strategies for sample 
preparation of human blood samples were evaluated including protein precipitation (PP) and 
solid phase extraction (SPE) on Waters Oasis® polymeric columns. Gradient 
chromatography within 15 min was performed on a Hypersil Polar-RP column combined 
with a Sciex API 2000 triple quadrupol instrument equipped with an electro-spray interface. 
Beta-agonists and beta-antagonists available on the Swedish market were included in the 
study. A combination of zinc sulphate and ethanol was found effective for PP. A clear 
supernatant was achieved that either could be injected directly on the LC–MS–MS system for 
analysis or transferred to a SPE column for further extraction and analyte concentration. 
Retention on the hydrophilic–lipophilic balanced sorbent HLB as well as the mixed mode 
cationic MCX and anionic MAX sorbents were investigated.33 
 Sameer Al-Rawithi, Sulaiman Al-Gazlan et al., This study describes an expedient 
assay for the analysis of the asthma medication, montelukast sodium (Singulair,MK-0476), in 
human plasma samples. After a simple extraction of the plasma, the drug and internal 
standard, quinine bisulfate, were measured by HPLC. The chromatographic system consisted 
of a single pump, a refrigerated autosampler, a C 4-mm particle size radial compression 
cartridge at 408C and a fluorescence detector with the excitation and emission 8 wavelengths 
set at 350 and 400 nm, respectively. The mobile phase which was delivered at 1.0 ml/min, 
was prepared by adding 200 ml of 0.025 M sodium acetate, pH adjusted to 4.0 with acetic 
acid, to 800 ml of acetonitrile, with 50 ml triethylamine. With a run time of only 10 min per 
sample, this assay had an overall recovery of .97% with a detection limit of 1 ng/ ml. The 
inter- and intra-run relative standard deviations at 0.05, 0.2 and 1.0 mg/ml were all ,9.2%,  
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while the analytical recovery at the same concentrations were within 7.7% of the amount 
added.34 
 Lucia Damascenoa, Rosa Ventura et al., A GC–MS procedure for the detection of 
different b-agonists in urine samples based on two consecutive derivatization steps is 
described. The derivatization procedure is based on the consecutive formation of cyclic 
methylboronate derivatives followed by a second derivatization step with MSTFA on the 
same extract, forming TMS derivatives. Injections in the GC–MS system may be carried out 
after each one of the derivatization steps, obtaining enough information for unambiguous 
identification. Limits of detection for the two derivatization steps ranged from 0.5 to 5 ng/ ml. 
This procedure was tested with the b-agonists bambuterol, clenbuterol, fenoterol, formoterol, 
salbutamol, salmeterol, a-hydroxy-salmeterol and terbutaline.35 
 W. Van Thuyne, P. Van Eenoo et al., A selective and sensitive screening method for 
the detection of prohibited narcotic and stimulating agents in doping control is described and 
validated. This method is suitable for the detection of all narcotic agents mentioned on the 
World Anti-Doping Agency (WADA) doping list in addition to numerous stimulants. The 
analytes are extracted from urine by a combined extraction procedure using CH2Cl2/MeOH 
(9/1, v/v) and t-butylmethyl ether as extraction solvents at pH 9.5 and 14, respectively. Prior 
to GC–MS analysis the obtained residues are combined and derivatised with MSTFA. The 
mass spectrometer is operated in the full scan mode in the range between m/z 40 and 550. The 
obtained limits of detection (LOD) for all components included in this extensive screening 
method are in the range 20–500 ng/ml, which is in compliance with the requirements set by 
WADA. Besides narcotic and stimulating agents, this method is also capable of detecting 
several agents with anti-estrogenic activity and some beta-agonists.36 
 Robert Papp, Pauline Luk et al., A rapid LC–MS/MS method was developed and 
partially validated for the quantitation of montelukast in spiked sheep plasma. A total run 
time of 1.5 min was achieved using a short monolithic column and employing a rapid 
gradient. Sample preparation involved protein precipitation with twofold acetonitrile by 
volume during which a deuterated internal standard (montelukast D-6) was incorporated. The 
MRM transitions for montelukast and the deuterated internal standard were 586/422 and 
592/427, respectively. A linear dynamic range of 0.25–500 ng/mL with a correlation  
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coefficient of 0.9999 was achieved. Precision was below 5%at all levels except at the LOQ 
(0.36 ng/mL) which demonstrated an overall of R.S.D. of 8%. Post-column infusion 
experiments were performed with precipitated plasma matrix and showed minimal 
interference with the peaks of interest.37 
Pattana Sripalakit, Bungon Kongthong et al., An analytical method based on high-
performance liquid chromatographic (HPLC) was developed for the determination of 
montelukast in human plasma using mefenamic acid as an internal standard. After 
precipitation of plasma proteins with acetonitrile, chromatographic separation was carried out 
using a Zorbax Eclipse® XDB C8 (150mm×4.6mm i.d., 5_m) with mobile phase consisted of 
methanol–acetonitrile–0.04M disodium hydrogen orthophosphate (22:22:56, v/v, pH 4.9). 
The wavelengths of fluorescence detectionwere set at 350nm for excitation and 450nm for 
emission. The linearity was confirmed in the concentration range of 5–1000 ng/ml 
inhumanplasma. Intra- and inter-day accuracy determined from quality control samples were 
101.50 and 107.24%, and 97.15 and 100.37%, respectively. Intra- and inter-day precision 
measured as coefficient of variation were ≤4.72 and ≤9.00%, respectively.38 
 Lida Liu, Haiyung Cheng et al., A steoreoselective high-performance liquid 
chromatographic method was developed for the quantification of montelukast (free acid of 
Singulair TM, or MK-0476), a potent and selective leukotriene D 4 (cysLTl) recptor 
antagonist, and it S-enantiomer (L-768,232). The method involves protein precipitation and 
fluorescence detection. Chromatographic separation of the enantiomers from endogenous 
components in plasma and chiral resolution of the enantiomers are achieved by using column 
switching HPLC and an :~-acid glycoprotein chiral column. The assay is linear in the range 
of 28.9-386 ng ml 1 of free acids of montelukast and L-768,232. The intraday precision (% 
relative standard deviation) values of this method were in the range of 2.5-9.1% for 
montelukast, and 2.4 6.8% for L-768,232, while the intraday accuracy values were in the 
range of 97-103% for montelukast and 96-104"/,, for L-768,232. The interday precision 
values of this method at 48.2 and 193 ng ml l were 5.3 and 3.6%, respectively, for 
montelukast, and 4.2 and 3.7°/,,, respectively, for L-768,232.39 
 Chester J. Kitchen, Amy Q. Wang et al., A simple, semi-automated, protein 
precipitation assay for the determination of montelukast (SINGULAIRTM, MK-0476) in  
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human plasma has been developed. Montelukast is a potent and selective antagonist of the 
cysteinyl leukotriene receptor used for the treatment of asthma. A Packard MultiPROBE†II 
EX is used to transfer 300 ml of plasma from sample, standard, and QC sample tubes to a 
microtiter plate (96-well). After addition of the internal standard by a repeating pipettor, a 
Tomtec QUADRA 96† adds 400 ml of acetonitrile to all plasma sample wells, 
simultaneously, in the microtiter plate. The Tomtec is also used to transfer the acetonitrile 
supernatant from the plasma protein precipitation step, batchwise, to another microtiter plate 
for analysis by HPLC with fluorescence detection. This assay has been validated and 
implemented for a clinical study of over 1300 plasma samples and is comparable to manual 
assays in the LLOQ (lower limit of quantitation, 3 ng/ml) and in stability. This is the first 
semi-automated protein precipitation assay published for the analysis of montelukast in 
human plasma and it results in significant time savings over the manual methods, both in 
sample preparation and in HPLC run time.40 
 A. Bartolinˇci´,  V. Druˇskovic et al., Suitable HPLC methods for the direct 
separation of bambuterol and albuterol enantiomers were developed. The enantioseparation 
was tested on numerous commercial chiral HPLC columns. For bambuterol the most 
convenient separation was determined on amylose Chiralpak AD column, and for albuterol 
on vancomycine Chirobiotic V column. The mobile phase compositions were systematically 
studied to obtain the optimal chromatographic methods. Validation of methods in selected 
conditions shows that the chosen methods are selective and precise with linear response of 
detector for both pairs of enantiomers.41 
Robin K. Harris , Paul Hodgkinson et al., Carbon-13 NMR spectra of the stable 
polymorphs of solid bambuterol hydrochloride (BHC) and terbutaline sulfate (TBS) are 
reported and the resonances assigned with the aid of solution-state spectra. A protocol is 
presented for quantification of BHC in a formulation in lactose, together with TBS, relative to 
a reference peak from magnesium stearate. This protocol compares the intensity of an 
aromatic signal of BHC with that of the main-chain methylene carbons of the stearate. It is 
shown that the limit of detection (LOD) of BHC in this system under the conditions described 
is 0.5% with an effective limit of quantification (LOQ) of 1.0%.42 
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Wenxia Luo, Lin Zhu et al., A chiral liquid chromatography–tandem mass spectrometry 
(LC–MS/MS) simultaneous stereoselective analysis of bambuterol and its active metabolite 
terbutaline enantiomers in Wistar rat plasma has been developed and validated. All analytes 
and the internal standard were extracted from rat plasma samples by liquid–liquid extraction, 
separated on macrocyclic glycopeptide teicoplanin column with mobile phase constituted of 
20mM ammonium acetate solution–methanol (10:90, v/v) at a flow-rate of 0.4 mL/min. 
Detection was performed on an API 3000 tandem mass spectrometer with positive 
electrospray ionization in multiple reaction monitoring mode. The calibration curves in the 
range 1–800 ng/mL were linear and the accuracy for each analyte was within 8.0%. The 
intra- and inter-day precision as determined from quality control samples was less than 
10.1%. The validated assay was successfully used to determine the enantiomers of 
bambuterol and terbutaline in rat plasma samples in the pharmacokinetic studies of rac-
bambuterol.43 
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AIM OF THE WORK 
                  The combination of an Anti-asthmatic drugs Montelukast Sodium     and 
Bambuterol HCl are selected for analysis by UV spectrophotometric method and reverse 
phase high performance liquid chromatography. 
                      It is estimated by simultaneous equation method as the λmax of  the drugs are 
dissimilar and their absorbance ratio lies outside the range 0.1 to 2. 
                   The next objective is to develop and validate a reverse phase high performance 
liquid chromatography which would be simple, rapid, efficient and reliable for the analysis of 
both the drugs in combined dosage form. 
 
 
SCHEME OF THE WORK 
 
            
 
Montelukast Sodium 
and Bambuterol HCl 
combined dosage form
UV Simultaneous 
equation method
Recovery Studies
Reverse Phase High 
Performance
Liquid Chromatography
Validation
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REVERSE PHASE HIGH PERFOMANCE LIQUID CHROMATOGRAPHY AND 
VALIDATION IN ESTIMATION OF MONTELUKAST SODIUM  AND  
BAMBUTEROL HYDROCHLORIDE IN COMBINED TABLET DOSAGE FORM. 
Instruments: 
¾ Shimadzu liquid chromatograph LC – 20 AT VP  
¾ Mettler Toledo AG 285 Balance CP-225D 
¾ DIGISUN-DI-707 pH meter 
¾ Millipore filter (10.45/ μm) 
¾ Whatman filter paper  
¾ Sonicator 
 
Reagents and Chemicals 
¾ Acetonitrile 
¾ HPLC grade water 
¾ Buffer 
REFERENCE STANDARDS: 
Montelukast Sodium and Bambuterol HCl: 
 These two reference standards were obtained as gift samples from Ceeal analytical 
laboratory,Chennai. The authenticity and purity of the sample was certified by the same. 
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Sample Tablet brand used             :  Montek-plus 
Label claim    :   Montelukast Sodium           - 10 mg 
                                                                Bambuterol HCl                   - 10 mg 
 
 METHOD DEVELOPMENT AND OPTIMIZATION: 
SELECTION OF WAVELENGTH: 
The known concentration of Montelukast Sodium and Bambuterol HCl were taken and 
dissolved in THF (Tetra hydro furan). The wavelength were tried from 200nm to 400nm  and 
the Peaks of the drugs were showing fronting and tailing.  The peak areas were also found to 
be minimum. Finally 230nm were selected for the analysis. 
OPTIMIZATION OF CHROMATOGRAPHIC PARAMETAERS 
(a) SELECTION OF MODE OF OPERATION: 
 As both the drugs were are polar in nature, a RP-HPLC method was Proposed. 
(b) SELECTION AND STANDARDISATION OF MOBILE PHASE: 
 MONTEK-PLUS is a combination of Montelukast sodium 10mg and Bambuterol HCl 
10mg. The method development of Montelukast sodium and Bambuterol HCl required 
adequate resolution of two drug peaks in the chromatogram. 
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DIFFERENT COMBINATIONS OF BUFFER AND SOLVENTS: 
                   Buffer(potassium dihydrogen ortho phosphate pH:3) and acetonitrile     (50:50) 
                   Buffer(potassium dihydrogen ortho phosphate pH:3) and acetonitrile (20:80)           
                   Buffer(potassium dihydrogen ortho phosphate pH:3) and acetonitrile (30:70) 
                   Buffer(potassium dihydrogen ortho phosphate pH:3) and methanol and   
acetonitrile (40:30:30),finally add 2.5% v/v THF 
                   Buffer(potassium dihydrogen ortho phosphate pH:3) and methanol and 
acetonitrile (45:20:35),finally add 5% v/v THF 
                    Peaks of Montelukast sodium and Bambutero HCl were well resolved with 
solvent system Buffer (Potassium dihydrogen phosphate pH:6 with dil KoH) 
acetonitril.(60:40). 
SELECTION OF FLOW RATE:              
 The Flow rate for Montelukast sodium and Bambuterol HCl were tried with 0.5ml, 
1ml, 1.5ml and 2ml, the peaks of the drugs were showing fronting and tailing with 0.5ml and 
2ml respectively and finally 2ml per minute was selected   for the analysis.  
PREPARATION OF BUFFER SOLUTION: 
Buffer solution was prepared by using 6.8g of potassiumdi hydrogen phosphate dissolved 
in 1000ml of HPLC grade water, pH adjusted to 6 with dil KoH, filtered through 0.45µ nylon 
membrane and degassed. 
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PREPARATION OF MOBILE PHASE: 
 Mix the Buffer and acetonitrile in the  ratio of  60:40 ,finally add 5% v/v THF and 
degass it.  Filtered through 0.45µ membrane. 
DILUENT 
 Mobile phase is used as diluent. 
DETERMINATION OF RETENTION TIME: 
(A) STANDARD SOLUTION OF MONTELUKAST SODIUM: 
 Accurately 104.6mg of Montelukast sodium was taken in a 100ml volumetric flask 
and dissolved in 10ml mobile phase, the volume was adjusted to 100ml with mobile phase. 5 
ml was taken in a separate 50ml volumetric flask and the volume was adjusted to 50 ml with 
mobile phase to get concentration of 100µg/ml of Montelukast sodium. 20µl of this solution 
was injected and chromatogram was obtained. 
(B) STANDARD SOLUTION OF BAMBUTEROL HCL: 
 Accurately 100.4mg of Bambuterol HCl was taken in a 100ml volumetric flask and 
dissolved in 10ml mobile phase,the volume was adjusted to 100ml with mobile phase. 5 ml 
was taken in a separate 50ml volumetric flask and the volume was adjusted to 50 ml with 
mobile phase to get concentration of 100µg/ml of Bambuterol HCl. 20µl of this solution was 
injected and chromatogram was obtained  
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(C) PREPARATION OF MIXED STANDARD SOLUTION: 
100.4mg of Bambuterol HCl and 104.6mg Montelukast sodium was transferred into a 
100ml dried volumetric flask.  The compounds were first dissolved in 10ml of THF and it 
was sonicated.  Then the volume was adjusted to 100ml with mobile phase. From the stock 
solution 5ml was transferred to a 50ml volumetric flask and the volume was adjusted to 
50ml with mobile phase to get a concentration of 100µg/ml of Bambuterol HCl and 
100µg/ml of Montelukast sodium . 20 µl  of the  resulting solution was injected and 
chromatogram was recorded . 
 
FIXED CHROMATOGRAPHIC CONDITIONS: 
INSTRUMENT               : Shimadzu liquid chromatograph 
      LC-20 AT VP     
COLUMN   : C18  
WAVELENGTH  : 230 nm 
TEMPERATURE  : Ambient temperature. 
FLOW RATE   : 2ml/min 
INJECTION VOLUME : 20µl. 
MOBILE PHASE  : Buffer (Potassium di hydrogen phosphate  
      pH:6) acetonitrile. (60:40), finally add 5%v/v THF 
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RETENTION TIME  : 4.270 min for Bambuterol HCl , 7.430 min  
  for Montelukast sodium 
QUANTITATIVE DETERMINATION OF THE DRUGS BY USING THE 
DEVELOPED METHOD 
Sample  : Montek-plus 
Label Claim  : Montelukast sodium – 10mg 
                                 Bambuterol HCl      - 10mg 
METHOD: 
 Twenty tablets were weighed and powdered.  570.2mg sample tablet MONTEK-
PLUS (equivalent to 104.6 mg of Montelukast sodium and 100.4 mg Bambuterol HCl) was 
taken into 100ml dried volumetric flask.  The powder was first dissolved in 5ml of THF and 
sonicated and finally the volume was adjusted to 100ml with mobile phase.  From this 
solution 5ml was transferred to 50ml volumetric flask and volume was adjusted to 50ml with 
mobile phase to get a concentration of 100µg/ml of Montelukast sodium and 100µg/ml of 
Bambuterol HCl. 20µl of the solution was injected and the chromatogram obtained. 
                                The amount of Montelukast sodium and Bambuterol HCl present in the 
tablet formulation was calculated by comparing the peak area of the standard and reports are 
given in Table-1 
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Amount of drug present in the tablet: 
 Sample area   Standard dilution      Potency 
--------------- x ----------------------- x------------x Average weight   
Standard area   Sample dilution     100 
 
   Amount present 
Percentage purity = --------------------x 100 
       Label claim 
 
Table-1           
Quantitative Estimation 
 
 
Acceptance critearia: 98-102%w/v 
 
S. 
No. 
Brand 
Name 
Content Label 
Claim 
(mg) 
Peak 
area 
Amoun
t 
present 
(mg) 
Percent 
Purity% 
w/v 
1. 
MONTEK-
PLUS 
Bambuterol HCl 10mg 2631.467 10.022 100.42% 
Montelukast sodium 10mg 2731.266 10.025 100.45% 
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ASSAY FOR BAMBUTEROL HCL: 
 
Amount Present =  
2455.716 
X 
100.4X50X50 
X 
99.68 
X   114.2=10.022 mg 
2455.686 1000X570.2X5 100 
 
 
% Label Claim = 
10.022 
X 100 = 100.22 % 
10 
                    
 
ASSAY FOR MONTELUKAST SODIUM:  
Amount Present =  
2649.254 
X 
104.6X50X50 
X 
99.54 
X   114.2=10.025 mg 
2656.278 1000X570.2X5 100 
 
% Label Claim = 
 10.025 
X 100 =100.25 % 
10 
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VALIDATION 
 Validation of an analytical method is a process to establish by laboratory studies that 
the performance characteristics of the method meet the requirements for the intended 
analytical application.  Performance characteristics are expressed in terms of analytical 
parameters. 
Design of experiment: 
Typical analytical parameters used in assay validation are, 
¾ Specificity 
¾ Linearity and range 
¾ Limit of quantification 
¾ Limit of detection 
¾ Accuracy 
¾ Precision 
- System precision 
- Method precision 
¾ Robustness 
¾ Ruggedness 
¾ System suitability studies 
- Resolution 
- Number of theoretical plates 
- The tailing factor. 
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SPECIFICITY 
 The specificity of an analytical method is its ability to measure accurately and 
specifically the analytes in the presence of compounds that may be expected to be present in 
the sample matrix. 
Determination: 
 The specificity of the analytical method was determined by injecting the placebo 
solution under the same experimental conditions as the assay. 
Preparation of placebo: 
 Placebo is prepared by mixing all the excipients without active ingredients. 
Procedure: 
¾ 100mg placebo was accurately weighed and transferred into a 25ml volumetric 
flask and the volume was made to 25ml with the mobile phase. The solution was 
filtered through Millipore filter paper and degassed.  20µl of this solution was 
injected and chromatogram was recorded . 
¾ 100.4mg of Bambuterol HCl and 104.6mg Montelukast sodium was transferred 
into a 100ml dried volumetric flask.  The compounds were first dissolved in 10ml 
of THF and it was sonicated.  Then the volume was adjusted to 100ml with mobile 
phase. From the stock solution 5ml was transferred to a 50ml volumetric flask and  
¾  
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the volume was adjusted to 50ml with mobile phase to get a concentration of 
100µg/ml of Bambuterol HCl and 100µg/ml of Montelukast sodium. 
¾  To this solution 100mg of placebo was added  and it was sonicated ,filtered 
through a Millipore filter paper. 20 µl  of the  resulting solution was injected and 
chromatogram was recorded.The mixed standard solution was also injected 
without placebo and it was recorded  and the reports are shown in Table-9 &10 
Table-9 
Specificity for Bambuterol HCl 
S.No. Sample Area obtained 
1. Standarad                2455.686 
2. Standard+Placebo 2454.420 
3. Placebo 0 
 
Table-10 
Specificity for Montelukast sodium 
S.No. Sample Area obtained 
1. Standarad 2656.278 
2. Standard+Placebo 2657.760 
3. Placebo 0 
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LINEARITY AND RANGE: 
 Linearity of an analytical method is its ability to elicit test result that are directly 
proportional to the concentration of analyte in  samples within a given range. 
Determination:   
  The linearity of the analytical method was determined by mathematical treatment of 
test result obtained by analysis of samples with analyte concentrations across the claimed 
range.  Area was plotted graphically as a function of analyte concentration.  Percentage curve 
fitting was calculated. 
Method: 
Preparation of mixed standard stock solution 
Accurately weighed 100.4mg of Bambuterol HCl and 104.6mg Montelukast sodium was 
transferred into a 100ml dried volumetric flask.  The compounds were first dissolved in 10ml 
of THF and then the volume was adjusted to 100ml with mobile phase. From the From the 
resulting solution, 4, 4.5, 5, 5.5, 6ml were transferred into 5 different 50ml volumetric flask.  
The volume was made with mobile phase to get a final concentration of 
80.32,90.36,100.4,110.44,120.48 µg/ml of Bambuterol HCl and 83.68, 94.14, 104.6, 115.06, 
125.52 µg/ml of Montelukast sodium. 20µl of the resulting solution was injected and 
chromatogram was recorded. 
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Acceptance Criteria 
¾ Correlation coefficient should not be less than 0.99 
The  linearity datas and analytical performance parameters of Bambuterol HCl and 
Montelukast sodium are shown in Table-11- 13 . 
Table-11 
LINEARITY DATA 
Bambuterol HCl 
S.No. Concentration(µg/ml) Peak Area 
1. 80.32 1973.618 
2.                       90.36 2221.115 
3. 100.4            2467.211 
4. 110.44            2716.779 
5. 120.48            2955.656 
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Table-12 
LINEARITY DATA 
Montelukast sodium 
 
S.No. Concentration(µg/ml) Peak Area 
1. 83.68 2126.738 
2.                      94.14 2398.281 
3. 104.60 2663.350 
4. 115.06 2926.429 
5. 125.52 3196.037 
 
 
 
Table-13 
ANALYTICAL PERFORMANCE PARAMETERS 
 
S. no. Drug name 
Linear 
dynamic 
range(µ/ml) 
Correlation 
coefficient 
Slope Intercept 
1. Bambuterol HCl (80.32-120.48) 0.999 53.71 82.615 
2. Montelukast 
sodium 
(83.68-125.52) 0.999 25.494 -4.505 
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ACCURACY 
 The accuracy of an analytical method is the closeness of the results obtained by that 
method to the true value.  Accuracy may often be expressed as percent recovery by the assay 
of known added amount of analyte. 
Determination: 
 The accuracy of the analytical method was determined by applying the method to the 
analysed samples to which known amounts of analyte had been added.  The accuracy was 
calculated from the  test results as the percentage of analyte recovered by the assay. 
Acceptance criteria: 
Percentage recovery should be within 98-102% 
PROCEDURE: 
Mixed standard stock solution 5ml and sample stock solution 5ml were mixed together in 50 
ml volumetric flask and the volume was made upto 50ml with mobile phase to get 100% 
range. Similarly 80% and 120% range was prepared. 20μl of this solution was injected three 
times and chromatograms were shown in the following graphs and values in table 14 and 15 . 
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Table-14 
Recovery Study of Bambuterol HCl 
 
S.No. RANGE Area obtained Amount 
Recovered(mg) 
% Recovery 
1. 80% 
1979.529 10.088 100.88 
1976.637         10.073 100.73 
1975.437 10.066 100.66 
2 100% 
2447.370 9.97 99.77 
2446.793 9.97 99.77 
2443.684          9.96 99.62 
3 120% 
2941.021 9.99 99.91 
2951.066 10.02 100.25 
2944.075 10.002 100.02 
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Table-15 
Recovery Study of Montelukast sodium 
 
S.No. RANGE Area 
obtained 
Amount 
Recovered(mg) 
% Recovery 
1. 80% 
2126.532 10.12 101.23 
2133.350 10.15 101.56 
2147.210 10.22 102.22 
2 100% 
2657.783 10.11 101.17 
2655.368  10.113 101.13 
2654.627  10.110 101.10 
3 120% 
3176.470 10.08 100.81 
3198.139 10.15 101.50 
3186.244 10.11 101.12 
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PRECISION 
 Precision of an analytical method is the degree of agreement among individual test 
results when the procedure is applied repeatedly to multiple sampling of a homogenous 
sample.  Precision of analytical method is usually expressed as the standard deviation and 
relative standard deviation. 
Determination: 
 The precision of the analytical method was determined by assaying sufficient number 
of sample and relative standard deviation was calculated. 
 The precision of the  instrument was determined by assaying the samples 
consecutively, number of time and relative standard deviation was calculated. 
Acceptance Criteria: 
 The relative standard deviation   should be with in 2% 
 
SYSTEM PRECISION : 
Accurately weighed 100.4mg of Bambuterol HCl and 104.6mg Montelukast sodium sodium 
was transferred into a 100ml dried volumetric flask.  The compounds were first dissolved in 
10ml of THF and then the volume was adjusted to 100ml with mobile phase. From the 
resulting solution 5ml was transferred into 50ml volumetric flask. The volume was made up 
with mobile phase to 50ml. 
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Method: 
 The system precision was evaluated by measuring 6 successive injection of 20µl of 
standard solution.  The peak response were measured from the following chromatogram  and 
system precision data area shown in Table-15&16. 
 
METHOD PRECISION: 
Procedure 
 Twenty tablets were weighed and powdered.  570.2mg sample tablet MONTEK-
PLUS(equivalent to 104.6mg of Montelukast sodium and 100.4mg Bambuterol HCl) was 
taken into 100ml dried volumetric flask.  The powder was first dissolved in 10ml of THF and 
sonicated and finally the volume was adjusted to 100ml with mobile phase.  From this 
solution 5ml was transferred to 50ml volumetric flask and volume was adjusted to 50ml with 
mobile phase to get a concentration of 100µg/ml of Montelukast sodium and 100µg/ml of 
Bambuterol HCl. 20µl of the solution was injected and the chromatogram obtained is shown 
in following graph. 
                                The amount of Montelukast sodium and Bambuterol HCl present in the 
tablet formulation was calculated by comparing the peak area of the standard and reports are 
given in Table-17-19 
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Table-15 
 System Precision data 
S.No. Area of Bambuterol HCl Area of Montelukast 
sodium 
1. 2441.405 2639.803 
2. 2446.671 2670.187 
3. 2453.085 2658.527 
4. 2458.308 2668.277 
5. 2445.602 2644.152 
6. 2455.507 2657.305 
MEAN 2450.097 2656.377 
S.D 2.9196 5.5226 
%RSD 0.119 0.002 
 
 
Table-16 
Relative 
Standard 
Deviation 
 
Bambuterol HCl Montelukast 
sodium 
Acceptance 
Criteria 
0.119 0.002 2% 
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Table-17 
Method Precision 0f Bambuterol HCl 
 
S.No. Area Obtained  Assay value in(mg) %  Label claim w/v 
1. 2455.716 10.0698 100.6% 
2. 2439.994 9.9837 99.83% 
3. 2450.901 10.002 100.02% 
4. 2442.650 9.94 99.4% 
5. 2457.210 10.08 100.8% 
6. 2446.320 9.97 99.7% 
 MEAN 2448.798 
 STANDARD DEVIATION 3.1272 
 RELATIVE STANDARD DEVIAION 0.0012 
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Table-18 
Method Precision 0f Montelukast sodium 
S.No. Area Obtained  Assay value in(mg) %  Label claim w/v 
1. 2649.254 10.046 100.4% 
2. 2652.369 9.944 99.4% 
3. 2629.900 99.903 99.03% 
4. 2632.810 9.878 98.78% 
5. 2656.440 10.05 100.5% 
6. 2645.434 9.96 99.6% 
 MEAN 2644.368 
 STANDARD DEVIATION 4.8069 
 RELATIVE STANDARD DEVIAION 0.0018 
                                                     
Table-19 
Relative 
Standard 
Deviation 
 
Bambuterol HCl Montelukast 
sodium 
Acceptance 
Criteria 
0.0012 0.0018 2% 
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Limit of detection (LOD) 
 It is the lowest amount of analyte in a sample that can be detected  but not  necessarily 
quantities  as an exact value  under  the stated, experimental conditions.  The detection limit 
is usually expressed as the concentration of analyte. 
It is given by 
               3.3 x σ 
L.O.D = ----------- 
                   m 
 σ = standard deviation of the response 
          m= slope of the calibration curve 
TABLE-20 
LIMIT OF DETECTION 
DRUG 
STANDARD 
DEVIATION 
SLOPE L.O.Dμg/ml 
BAMBUTEROL 
HCL 
15.874 24.499 2.1382 
MONTELUKAST 
SODIUM 
16.538 25.494 2.1407 
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Limit of Quantitation: 
 The Quantitation limit of an analytical procedure is the lowest amount of analyte 
which can be Quantitatively determined with suitable Precision  and Accuracy.  
It is  given by  
                  10xσ 
L.O.Q = ------------- 
                    m 
                   σ = standard deviation of the response 
                    m= slope of the calibration curve 
TABLE-21 
LIMIT OF QUANTITATION 
DRUG 
STANDARD 
DEVIATION 
SLOPE L.O.Q μg/ml 
BAMBUTEROL 
HCL 
15.874 24.499 6.4794 
MONTELUKAST 
SODIUM 
16.538 25.494 6.4870 
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 RUGGEDNESS 
 The Ruggedness of an analytical method is degree of reproducibility of test result 
obtained by the analysis of the same sample under a variety  of normal test condition, such as 
different laboratories, different analyst, different instruments, different lots of reagents, 
different elapsed assay times, different assay temperature, different days, etc. 
 Ruggedness is normally expressed as the lack of influence on test result of operational 
and environmental variables of the analytical method. 
Determination: 
 The ruggedness of an analytical method was determined by analysis of aliquots from 
homogeneous lots by different analysts using operational and environmental conditions that 
may differ but were still with in the specified parameters of the assay.  The degree of 
reproducibility of test result was then determined as a function of the assay variables.  This 
reproducibility was assayed under normal conditions to obtain a measure of the ruggedness of 
analytical method. 
 The assay of BAMBUTEROL HCL and MONTELUKAST SODIUM were 
performed in different conditions like different analyst on different days. 
Method: 
The  standard and sample  solutions were prepared by different analysts on different 
days and the resulting solution were injected and chromatograms are recorded and  shown in  
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following graphs and ruggedness of the  method and report of Bambuterol HCl and 
Montelukast sodium are shown in Table 22. 
Table-22 
RUGGEDNESS 
 
Analyst 
 
Date 
Amount Found %purity 
 
Bambuterol 
HCl 
mg 
Montelukast 
sodium 
mg 
Bambuterol 
HCl 
Montelukast 
sodium 
I 17/12/200
9 
9.968 10.012 99.68 100.12 
II 18/12/200
9 
9.95 10.042 99.5 100.7 
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ROBUSTNESS 
Robustness of an analytical method is measure of its capacity to remain unaffected by 
small but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage. 
Determination: 
 The robustness of an analytical method was determined by analysis of aliquots from 
homogenous lots by differing physical parameters that may differ but were still within the 
specified parameter of the assay for example change in physical parameters like flow rate and 
lambda max. 
Method: 
Standard solution preparation: 
100.4mg of Bambuterol HCl and 104.6mg Montelukast sodium was transferred into a 
100ml dried volumetric flask.  The compounds were first dissolved in 10ml of THF.Then the 
volume was adjusted to 100ml with mobile phase. From the stock solution 5ml was 
transferred to a 50ml volumetric flask and the volume was adjusted to 50ml with mobile 
phase to get a concentration of 100µg/ml of Bambuterol HCl and 100µg/ml of Montelukast 
sodium.  
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Sample preparation: 
Twenty tablets were weighed and powdered.  570.2mg sample tablet MONTEK-
PLUS(equivalent to 104.6mg of Montelukast sodium and 100.4mg Bambuterol HCl) was 
taken into 100ml dried volumetric flask.  The powder was first dissolved in 10ml of THF and 
sonicated and finally the volume was adjusted to 100ml with mobile phase.  From this 
solution 5ml was transferred to 50ml volumetric flask and volume was adjusted to 50ml with 
mobile phase to get a concentration of 100µg/ml of Montelukast sodium and 100µg/ml of 
Bambuterol HCl. 20µl of the solution was injected and the chromatogram obtained is shown 
in following graphs. 
                                The amount of Montelukast sodium and Bambuterol HCl present in the 
tablet formulation was calculated by comparing the peak area of the standard and reports are 
given in Table-23-30 
 
Table 23 
Chromatographic condition 
 flow rate  2ml/min 
Column C18 
Wave length 230nm 
Temperature Ambient 25oc 
Injection Volume 20µl 
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Table 24 
Change in Organic phase +10% 
S.No. Drug        Standard Area Sample Area % Purity w/v 
1. Bambuterol 
HCl 
2165.169 2188.211 102.7 
2. Montelukast 
sodium 
1503.266 1507.421 100.6 
 
 
 
Table 25 
Chromatographic condition:-  
Change in flow rate 2ml/min 
Column C18 
Wave length 230nm 
Temperature Ambient25oc 
Injection Volume 20µl 
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Table 26 
Change in organic phase -10% 
S.No. Drug Standard Area Sample Area % Purity w/v 
1. Bambuterol 
HCl 
2509.217 2501.504 99.80 
2. Montelukast 
sodium 
1586.911 1582.612 100.1 
 
 
Table 27 
Chromatographic condition: - change in Lambda max 230 nm 
 flow rate 2.0 ml/min 
Column C18 
Wave length 230nm 
Temperature Ambient25oc 
Injection Volume 20µl 
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Table 28 
Change in Lambda max 232 nm 
S.No. Drug Standard Area Sample Area % Purity w/v 
1. Bambuterol 
HCl 
2446.667 2443.332 99.9 
2. Montelukast 
sodium 
2646.951 2645.612 100.4 
 
 
 
Table 29 
Chromatographic condition:- change in Lambda max 228 nm 
 flow rate 2.0 ml/min 
Column C18 
Wave length 267nm 
Temperature Ambient25oc 
Injection Volume 20µl 
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Table 30 
Change in Lambda max 228 nm 
S.No. Drug Standard Area Sample Area % Purity w/v 
1. Bambuterol 
HCl 
2097.491 2095.237 100.01 
2. Montelukast 
sodium 
2455.953 2456.413 100.4 
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SYSTEM SUITABILITY PARAMETERS 
 System suitability testing is an integral part of many analytical procedures.  The test is 
based on the concept that the equipment, electronics, analytical operation and sample to be 
analysed constitute an integral system that can be evaluated as such.  System suitability test 
parameters to be established for  a particular procedure depend on the type of procedure 
being validated. 
Method: 
 A solution of  100.1 µg/ml Bambuterol HCl  and 104.6 µg/ml   were prepared by 
diluting with  mobile phase and same was injected and a chromatogram was recorded and 
they are shown in the following graph and system suitability report are shown in the 
following Table-31 
Table 31 
System suitability parameters 
S.No. Parameters Bambuterol HCl Montelukast 
sodium 
1. Theoretical plates 10133 12505 
2. Tailing factor 1.074 1.023 
3. Resolution 14.520 
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UV SPECTROPHOTOMETRIC SIMULTANEOUS EQUATION METHOD OF 
MONTELUKAST SODIUM AND BAMBUTEROL HCl IN COMBINED TABLET 
DOSAGE FORM 
PRINCIPLE: 
If a sample contains two absorbing drugs (X and Y) each of which absorbs at the λmax 
of the other. It may be possible to determine the quantity of both drugs by the technique of 
simultaneous equation (or) Vierodt’s method. 
Criteria for obtaining maximum precision, based upon absorbance ratios have been 
suggested that place limits on the relative concentrations of the component of the mixture. 
   A2 / A1 and  ay2 / ay1 
   ax2 / ax1   A2 / A1 
Where  ax1, ax2 = Absorptivities of X at λ1 and λ2 
  ay1, ay2 = Absorptivities of X at λ1 and λ2 
A1, A2 = Absorbances of the diluted sample at λ1 and  λ2. 
The ratio should lie outside the range of 0.1 – 2.0 for the precise determination of (Y 
and X) two drugs respectively. 
These criteria are satisfactory only when the λmax of the two components is reasonably 
dissimilar. The additional criteria includes that two components do not interact chemically,  
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there by negating the initial assumption that the total absorbance is the sum of the 
individual absorbances. 
 
   MATERIALS 
Market Sample: Montek Plus 
LABEL CLAIM:  
                    Montelukast sodium            -10 mg 
                    Bambuterol Hcl                    -10 mg 
Equipments Used: 
¾ ATCO Balance 
¾ SHIMADZU UV - & spectrophotometer double beam digital 
UV-1700 
 
Solvent Used: 
¾ Methanol AR 
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FIXATION OF VARIOUS PARAMETERS (Montelukast Sodium) 
λmax 
The wavelength at which maximum absorption takes is place called λmax 
Determination of Absorption Maximum (λmax) for Montelukast Sodium  
Procedure: 
 100mg of authentic Montelukast Sodium sample was accurately weighed and 
transferred to 100ml volumetric flask and 10ml methanol was added, dissolved and the 
volume was made upto 100ml with methanol. 
 10ml of this stock solution was pipetted out in to separate 100ml volumetric flask and 
the volume was made up to 100ml with methanol. From this  10ml of solution was pipetted 
out in to separate 100ml volumetric flask and the volume was made up to 100ml with 
methanol.  
            The absorbance of solution was measured against solvent blank in UV-region of 200-
400nm. The λmax was found to be 280nm.  
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BEER’S LAW PLOT FOR MONTELUKAST SODIUM 
PROCEDURE 
             100mg of authentic Montelukast Sodium sample was accurately weighed and 
transferred to 100ml volumetric flask and 10ml methanol was added, dissolved and the 
volume was made upto 100ml with methanol. 
 10ml of this stock solution was pipetted out in to separate 100ml volumetric flask and 
the volume was made up to 100ml with methanol. 
  From this aliquots of 4ml, 8ml, 12ml, 16ml, 20ml, 24ml was pipetted out in to 
separate 100ml volumetric flask. Then the volume was made upto 100ml with methanol. The 
absorbance of each solution was found out at 280nm against a reagent blank. The readings 
are presented in Table-32 and  the following graph A. 
     
 
 
 
 
 
 
 
 
 
 
 
72 
 
Chapter V                                                                                                                          UV Analysis 
 
Table – 32 
DATA FOR BEER’S LAW PLOT OF MONTELUKAST SODIUM  
(Linearity) 
S.No. Concentration μg/ml Absorption  
1 4 0.098  
2 8 0.198  
3 12 0.299  
4 16 0.401  
5 20 0.502  
6 24 0.602  
 
 
Linearity Co-efficient (γ )       =  0.995 
SLope (m)                         = 0.0252 
 Intercept(c)                            =     
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DEVIATIONS FROM BEER’S LAW 
 For the drug Montelukast sodium maximum deviation was found in the 
Concentration range above 36μg/ml.  The readings are presented in  
Table -33 and the following graph B. 
Table -33 
DATA FOR DEVIATIONS FORM BEER’S LAW PLOT FOR  
MONTELUKAST SODIUM  
S.No. Concentration μg/ml Absorbance 
1. 4 0.098 
2. 8 0.198 
3. 12 0.299 
4. 16 0.401 
5. 20 0.502 
6. 24 0.602 
7. 28 0.712 
8. 32 0.828 
   9. 36 0.843 
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Determination of Absorption Maximum (λmax) for Bambuterol Hcl 
    The literature survey shows that there is no specific λmax for bambuterol Hcl. 
I also confirmed it. But some studies was carried out by taking 210-215nm as a working 
standard. So I carried out this work by taking 212 nm as a working standard for bambuterol 
Hcl. 
 
BEER’S LAW PLOT FOR BAMBUTEROL HCl 
PROCEDURE 
             100mg of authentic bambuterol Hcl. sample was accurately weighed and transferred 
to 100ml volumetric flask and methanol was added, dissolved and the volume was made upto 
100ml with methanol. 
 10ml of this stock solution was pipetted out in to separate 100ml volumetric flask and 
the volume was made up to 100ml with methanol. 
  From this aliquots of 4ml, 8ml, 12ml, 16ml, 20ml, 24ml was pipetted out in to 
separate 100ml volumetric flask. Then the volume was made upto 100ml with methanol. The 
absorbance of each solution was found out at 212nm against a reagent blank. The readings 
are presented in Table-34 and the following graph c. 
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Table – 34 
DATA FOR BEER’S LAW PLOT OF BAMBUTEROL HCl 
 
(Linearity) 
S.No. Concentration μg/ml Absorption  
1 4 0.212  
2 8 0.418  
3 12 0.632  
4 16 0.851  
5 20 1.070  
6 24 1.285  
 
 
Linearity Co-efficient (γ )        = 0.993 
 SLope (m)    = 0.0538 
 Intercept(c)                        =  
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DEVIATIONS FROM BEER’S LAW 
 For the drug Bambuterol HCl maximum deviation was found in the Concentration 
range above 28μg/ml.  The readings are presented in  
Table -35 and the following graph D. 
Table -35 
DATA FOR DEVIATIONS FROM BEER’S LAW PLOT FOR  
BAMBUTEROL HCl 
S.No. Concentration μg/ml Absorbance 
1. 4 0.212 
2. 8 0.418 
3. 12 0.632 
4. 16 0.851 
5. 20 1.070 
6. 24 1.285 
7. 28 1.301 
8. 32 1.324 
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Preparation of sample solution 
 Ten tablets are weighed and average weight was calculated. The tablets are ground to 
a fine powder. A powder equivalent to 10mg of Montelukast Sodium  and 10mg of 
Bambuterol Hcl was accurately weighed and transferred to 100ml volumetric flask and 
methanol was added and shaken until it dissolves and the volume was made upto 100ml with 
methanol. This solution was filtered through whatmann filter paper.  
 From this 10ml was pipetted out in to separate 100ml volumetric flask and the volume 
was made up to 100ml with methanol. From this aliquots  any one concentration (4ml or 8ml, 
12ml, 16ml, 20ml, 24ml) was pipetted out in to separate 100ml volumetric flask. Then the 
volume was made upto 100ml with methanol 
 The absorbance of each solution was found out at 280nm (λmax of  Montelukast 
Sodium  ) and 212nm (Working standard for Bambuterol Hcl) against a reagent blank. 
The analysis values are given in Table-36 
 
Calculation: 
 λ1 = 280nm (λmax of Montelukast Sodium) 
 λ2 = 212nm (Working standard for Bambuterol Hcl) 
 X – Montelukast Sodium   
 Y – Bambuterol Hcl 
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ax1 and ax2 – Absorptivities of Montelukast Sodium at  λ1 and λ2 
ay1 and ay2 – Absorptivities of Bambuterol Hcl at λ1 and λ2  
Cx and Cy – Concentration of Montelukast Sodium and Bambuterol Hcl 
  (Sample) in grams per 100ml 
A1 and A2 – Absorbance of sample at λ1 and λ2     
Absorptivity (a) = A/bc = 
Absorbance 
b x concentration of substance 
Determination of Cx and Cy 
 
Cx = 
A2ay1-A1ay2 
ax2 ay1- ax1 ay2 
 
 
Cy = 
A1ax2-A2ax1 
ax2 ay1- ax1 ay2 
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Table36 
Absorbance values for standard and sample 
Wavelength 
Montelukast 
Sodium  Bambuterol Hcl Sample 
 
280 
λ1 
Montelukast Sodium 
0.502 0.145 0.271 
 
212 
λ2 
      Bambuterol Hcl 
0.091 0.851 0.0472 
 
 
Table-36a 
 
Absorptivity values for Montelukast Sodium and  Bambuterol Hcl 
 
Parameter 
Absorptivity at  280nm Absorptivity at 212nm 
Montelukast 
Sodium   
Bambuterol Hcl 
 
Montelukast 
Sodium 
Bambuterol Hcl 
 
*Mean 0.35 0.1046 0.0755 0.7446 
SD 0.6633 0.3577 0.3924 0.2366 
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*  Absorptivity values are the mean of six determinations. S.D. is standard deviation.  ax1 and 
ax2 are absorptivities of Montelukast Sodium  at 280 nm, and 212nm, respectively; ay1 and 
ay2 are absorptivities of Bambuterol HCl at 280nm and 212nm respectively. 
 
CRITERIA FOR OBTAINING MAXIMUM PRECISION 
                               (A2 / A1)/ (ax2 / ax1) and (ay2 / ay1)/ (A2 / A1)  
was found to be 0.9611 and 0.9781 respectively. This ratio should lie outside the range 0.1-
2.0 for the precise determination. 
Table-36b 
Analysis data of tablet formulations 
 
Parameters 
UV-spectrophotometry 
Montelukast 
Sodium   
Bambuterol HCl 
Label Claim 10mg 10mg 
Amount found 10.11 mg  9.95 mg 
*% Drug content 101.1% 99.5% 
S.D. 1.8172                0.18289 
% R.S.D 1.8152 0.1827 
                    
• value for % Drug content are mean of five estimations 
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RECOVERY STUDIES 
 To check the accuracy of the developed method and to study the interference of 
formulation additives, analytical recovery experiments were carried out by standard addition 
method at 80, 100 and 120% level. From the total amount of drug found the percentage 
recovery was calculated. The results are reported in Table-37 
Table 37 
Recovery studies 
Montelukast Sodium 
Range *Recovery % R.S.D 
80% 101.23 0.8020 
100% 101.13 0.6435 
120% 100.81 0.4765 
 
Bambuteol HCl 
Range *Recovery % R.S.D 
80% 100.66 0.1823 
100% 99.77 0.1000 
120% 99.91 0.1674 
 
*Recovery is the mean of three estimations 
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RESULTS AND DISCUSSION 
Montelukast sodium and Bambuterol HCl 
 UV spectrophotometry by simultaneous equation method and reverse phase high 
performance liquid chromatography were developed for analysing Montelukast sodium and 
Bambuterol HCl in combined tablet dosage form. 
 For UV spectrophotometry linearity was obtained in the concentration range of 4 to 
32 μg/ml for Montelukast sodium and 4 to 28 μg/ml for Bambuterol HCl. In quantitative 
determination the % Drug content was found to be 101.1% and 99.5% for Montelukast 
sodium and Bambuterol HCl respectively. Recovery experiments were performed and it was 
within 98 – 102%, the percentage relative standard deviation were found to be <2% which 
shows high precision and accuracy of the method. 
 In HPLC method, HPLC conditions were optimized to obtain an adequate separation 
of eluted compounds. Initially various mobile phase were tried, to separate drugs. Mobile 
phase and flow rate selection was based on peak parameters (height, tailing, theoretical 
plates, etc). The system with buffer (Potassium hydrogen phosphate pH6): Acetonitrile : 
methanol (60:40v/v) with 2 ml/min flow rate is quite robust. The optimum wavelength for 
detection was 230nm at which better detector response for drugs was obtained. The average 
retention times for 4.28 min for Bambuterol HCl ,7.4 min for Montelukast sodium 
respectively. 
 According to USP system suitability test are an integral part of chromatographic 
method. They are used to verify the reproducibility of the chromatographic system. To  
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ascertain its effectiveness, system suitability tests were carried out on freshly prepared stock 
solution. The parameters are shown in table 31. 
 The calibration curve was found to be linear for both Bambuterol HCl & Montelukast 
sodium. 
 The low values of % RSD indicate the method is precise and accurate. The developed 
method was very specific without the interference of excipients. 
The percentage purity was 99.97% and 100.8% for Bambuterol HCl and Montelukast 
sodium respectively. 
 The mean recoveries were found to be in the range of 98% to 102%. 
 Limit of detection for Bambuterol HCl and Montelukast sodium was found to be 
2.1382 μg/ml & 2.1407 μg/ml respectively. 
 Limit of quantitation for Bambuterol HCl and Montelukast sodium was found to be 
6.4794 μg/ml & 6.4870 μg/ml respectively. 
Robustness of the proposed method was determined by changing the wavelength and 
flow rate. 
 Ruggedness of proposed method was determined by analysis of aliquots from 
homogenous slot by different analyst in different days using similar operational 
environmental condition. The results were within 98-102%. 
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